# A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

> **NCT06183216** · PHASE1 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 140 (actual)

## Conditions studied

- Pneumococcal Infectious Disease

## Interventions

- **BIOLOGICAL:** Sinovac PCV13
- **BIOLOGICAL:** PREVNAR 13

## Key facts

- **NCT ID:** NCT06183216
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-04
- **Primary completion:** 2025-03-26
- **Final completion:** 2025-03-26
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06183216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06183216, "A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06183216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*